Form 8-K Jounce Therapeutics, For: Aug 07
Last jounce therapeutics, inc earnings: 2/27 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations: ir.jouncetx.com
| Impact snapshot | Event time: | JNCE | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last price | ||
| VWAP | ||
|
High:
|
Max up |
High:
|
|
Low:
|
Max down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event Day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance Since Event
Time and Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
SIGN UP TODAY
Opt-in for
JNCE alerts
JNCE alerts
from News Quantified
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JNCE alerts
High impacting Jounce Therapeutics, Inc news events
Weekly update
A roundup of the hottest topics
JNCE
News
- Enrollment underway in Jounce Therapeutics' early-stage JTX-8064 study in solid tumors [Seeking Alpha]Seeking Alpha
- Jounce Therapeutics Announces Initiation of Phase 1 INNATE Study of JTX-8064 (LILRB2/ILT4 Inhibitor) Monotherapy and PD-1 Inhibitor Combination Therapy in Patients with Advanced Solid TumorsGlobeNewswire
- Jounce Therapeutics to Present at Upcoming Investor Conferences in JanuaryGlobeNewswire
- Jounce Therapeutics, Inc. (<a href="https://www.marketbeat.com/stocks/NASDAQ/JNCE/price-target/">NASDAQ: JNCE</a>) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating.MarketBeat
- Jounce Therapeutics Added to NASDAQ Biotechnology IndexGlobeNewswire
- More
JNCE
SEC Filings
- 1/20/21 - Form 4
- 1/11/21 - Form 4
- 1/11/21 - Form 4
- JNCE's page on the SEC website
- More